nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—CHRM3—nephrolithiasis	0.932	1	CbGaD
Dicyclomine—CHRM3—ureter—nephrolithiasis	0.0115	0.785	CbGeAlD
Dicyclomine—CHRM1—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00387	0.191	CbGpPWpGaD
Dicyclomine—CHRM2—Muscarinic acetylcholine receptors—CHRM3—nephrolithiasis	0.00382	0.188	CbGpPWpGaD
Dicyclomine—Numbness—Hydrochlorothiazide—nephrolithiasis	0.00185	0.0557	CcSEcCtD
Dicyclomine—Sensory loss—Hydrochlorothiazide—nephrolithiasis	0.00177	0.0533	CcSEcCtD
Dicyclomine—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.00122	0.0368	CcSEcCtD
Dicyclomine—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00109	0.033	CcSEcCtD
Dicyclomine—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00107	0.0323	CcSEcCtD
Dicyclomine—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00105	0.0317	CcSEcCtD
Dicyclomine—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.001	0.0303	CcSEcCtD
Dicyclomine—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.000981	0.0295	CcSEcCtD
Dicyclomine—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.000967	0.0292	CcSEcCtD
Dicyclomine—CHRM3—renal system—nephrolithiasis	0.000911	0.0624	CbGeAlD
Dicyclomine—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.000885	0.0267	CcSEcCtD
Dicyclomine—CHRM3—kidney—nephrolithiasis	0.000881	0.0603	CbGeAlD
Dicyclomine—CHRM1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.000856	0.0422	CbGpPWpGaD
Dicyclomine—CHRM2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.000845	0.0416	CbGpPWpGaD
Dicyclomine—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.000765	0.0231	CcSEcCtD
Dicyclomine—CHRM1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.000719	0.0354	CbGpPWpGaD
Dicyclomine—CHRM2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00071	0.035	CbGpPWpGaD
Dicyclomine—CYP1A1—renal system—nephrolithiasis	0.000682	0.0467	CbGeAlD
Dicyclomine—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00067	0.0202	CcSEcCtD
Dicyclomine—CYP1A1—kidney—nephrolithiasis	0.000659	0.0452	CbGeAlD
Dicyclomine—Tension—Hydrochlorothiazide—nephrolithiasis	0.000657	0.0198	CcSEcCtD
Dicyclomine—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00065	0.0196	CcSEcCtD
Dicyclomine—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.000631	0.019	CcSEcCtD
Dicyclomine—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.000621	0.0187	CcSEcCtD
Dicyclomine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.000615	0.0185	CcSEcCtD
Dicyclomine—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.000612	0.0184	CcSEcCtD
Dicyclomine—Malaise—Hydrochlorothiazide—nephrolithiasis	0.000604	0.0182	CcSEcCtD
Dicyclomine—Syncope—Hydrochlorothiazide—nephrolithiasis	0.0006	0.0181	CcSEcCtD
Dicyclomine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.000592	0.0178	CcSEcCtD
Dicyclomine—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.000588	0.0177	CcSEcCtD
Dicyclomine—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.000563	0.017	CcSEcCtD
Dicyclomine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000557	0.0168	CcSEcCtD
Dicyclomine—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.000551	0.0166	CcSEcCtD
Dicyclomine—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.000546	0.0165	CcSEcCtD
Dicyclomine—Oedema—Hydrochlorothiazide—nephrolithiasis	0.000546	0.0165	CcSEcCtD
Dicyclomine—Shock—Hydrochlorothiazide—nephrolithiasis	0.000538	0.0162	CcSEcCtD
Dicyclomine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.000533	0.0161	CcSEcCtD
Dicyclomine—CHRM1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000525	0.0258	CbGpPWpGaD
Dicyclomine—CHRM3—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000523	0.0258	CbGpPWpGaD
Dicyclomine—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.000521	0.0157	CcSEcCtD
Dicyclomine—CHRM2—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000518	0.0255	CbGpPWpGaD
Dicyclomine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.000494	0.0149	CcSEcCtD
Dicyclomine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.000491	0.0148	CcSEcCtD
Dicyclomine—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.000487	0.0147	CcSEcCtD
Dicyclomine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.000486	0.0146	CcSEcCtD
Dicyclomine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.000481	0.0145	CcSEcCtD
Dicyclomine—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.000475	0.0143	CcSEcCtD
Dicyclomine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000471	0.0142	CcSEcCtD
Dicyclomine—Pain—Hydrochlorothiazide—nephrolithiasis	0.000467	0.0141	CcSEcCtD
Dicyclomine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000467	0.0141	CcSEcCtD
Dicyclomine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00045	0.0136	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000447	0.0135	CcSEcCtD
Dicyclomine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.000434	0.0131	CcSEcCtD
Dicyclomine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000432	0.013	CcSEcCtD
Dicyclomine—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000403	0.0121	CcSEcCtD
Dicyclomine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000392	0.0118	CcSEcCtD
Dicyclomine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000387	0.0117	CcSEcCtD
Dicyclomine—CHRM2—GPCRs, Other—CHRM3—nephrolithiasis	0.000375	0.0185	CbGpPWpGaD
Dicyclomine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000361	0.0109	CcSEcCtD
Dicyclomine—CHRM2—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00036	0.0177	CbGpPWpGaD
Dicyclomine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000347	0.0105	CcSEcCtD
Dicyclomine—Rash—Hydrochlorothiazide—nephrolithiasis	0.000345	0.0104	CcSEcCtD
Dicyclomine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000344	0.0104	CcSEcCtD
Dicyclomine—Headache—Hydrochlorothiazide—nephrolithiasis	0.000342	0.0103	CcSEcCtD
Dicyclomine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000325	0.00978	CcSEcCtD
Dicyclomine—CHRM1—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000296	0.0146	CbGpPWpGaD
Dicyclomine—CHRM3—G alpha (q) signalling events—DGKH—nephrolithiasis	0.000295	0.0145	CbGpPWpGaD
Dicyclomine—CYP1A1—Biological oxidations—SLC26A1—nephrolithiasis	0.000281	0.0138	CbGpPWpGaD
Dicyclomine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000264	0.013	CbGpPWpGaD
Dicyclomine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.000263	0.013	CbGpPWpGaD
Dicyclomine—CHRM1—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000256	0.0126	CbGpPWpGaD
Dicyclomine—CHRM1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000256	0.0126	CbGpPWpGaD
Dicyclomine—CHRM2—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000253	0.0125	CbGpPWpGaD
Dicyclomine—CHRM2—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000253	0.0125	CbGpPWpGaD
Dicyclomine—CHRM1—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.000214	0.0105	CbGpPWpGaD
Dicyclomine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000191	0.00941	CbGpPWpGaD
Dicyclomine—CHRM1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000165	0.00814	CbGpPWpGaD
Dicyclomine—CHRM2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000163	0.00803	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000142	0.00697	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00014	0.00688	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000125	0.00614	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—RGS14—nephrolithiasis	0.000124	0.00612	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—RGS14—nephrolithiasis	0.000123	0.00606	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—RGS14—nephrolithiasis	0.000113	0.00558	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—RGS14—nephrolithiasis	0.000113	0.00556	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—RGS14—nephrolithiasis	0.000112	0.00551	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000108	0.00531	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—CHRM3—nephrolithiasis	0.000106	0.00524	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—PTH—nephrolithiasis	9.86e-05	0.00485	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—PTH—nephrolithiasis	9.82e-05	0.00484	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—PTH—nephrolithiasis	9.73e-05	0.00479	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—DGKH—nephrolithiasis	8.42e-05	0.00415	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—DGKH—nephrolithiasis	8.4e-05	0.00414	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—DGKH—nephrolithiasis	8.31e-05	0.0041	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—GRHPR—nephrolithiasis	7.97e-05	0.00393	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ADCY10—nephrolithiasis	7.87e-05	0.00387	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ADCY10—nephrolithiasis	7.84e-05	0.00386	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ADCY10—nephrolithiasis	7.77e-05	0.00383	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—DGKH—nephrolithiasis	7.65e-05	0.00377	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—DGKH—nephrolithiasis	7.62e-05	0.00376	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—DGKH—nephrolithiasis	7.55e-05	0.00372	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—AGXT—nephrolithiasis	7.11e-05	0.0035	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—RGS14—nephrolithiasis	6.69e-05	0.00329	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—RGS14—nephrolithiasis	6.67e-05	0.00328	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—RGS14—nephrolithiasis	6.6e-05	0.00325	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GRHPR—nephrolithiasis	6.33e-05	0.00312	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CHRM3—nephrolithiasis	6.09e-05	0.003	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—SLC26A1—nephrolithiasis	6.04e-05	0.00298	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—APRT—nephrolithiasis	6.04e-05	0.00298	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CHRM3—nephrolithiasis	6.01e-05	0.00296	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—AGXT—nephrolithiasis	5.65e-05	0.00278	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PTH—nephrolithiasis	5.57e-05	0.00274	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PTH—nephrolithiasis	5.55e-05	0.00273	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CHRM3—nephrolithiasis	5.53e-05	0.00272	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PTH—nephrolithiasis	5.5e-05	0.00271	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CHRM3—nephrolithiasis	5.46e-05	0.00269	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PTH—nephrolithiasis	5.06e-05	0.00249	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PTH—nephrolithiasis	5.04e-05	0.00248	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PTH—nephrolithiasis	4.99e-05	0.00246	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—SLC26A1—nephrolithiasis	4.8e-05	0.00236	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—APRT—nephrolithiasis	4.8e-05	0.00236	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—DGKH—nephrolithiasis	4.52e-05	0.00223	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.52e-05	0.00223	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—DGKH—nephrolithiasis	4.5e-05	0.00222	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.5e-05	0.00222	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—DGKH—nephrolithiasis	4.46e-05	0.0022	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.46e-05	0.0022	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—AQP1—nephrolithiasis	4.31e-05	0.00212	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—AQP1—nephrolithiasis	3.42e-05	0.00168	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CHRM3—nephrolithiasis	3.27e-05	0.00161	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CHRM3—nephrolithiasis	3.22e-05	0.00159	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CHRM3—nephrolithiasis	3.09e-05	0.00152	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PTH—nephrolithiasis	2.99e-05	0.00147	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PTH—nephrolithiasis	2.98e-05	0.00147	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PTH—nephrolithiasis	2.95e-05	0.00145	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SPP1—nephrolithiasis	1.5e-05	0.000739	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SPP1—nephrolithiasis	1.5e-05	0.000736	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SPP1—nephrolithiasis	1.48e-05	0.000729	CbGpPWpGaD
